Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Shen, Jie; Chen, Zhen; Zhuang, Qianfeng; Fan, Min; Ding, Tao; Lü, Hao; He, Xiaozhou

doi:10.1371/journal.pone.0166482

Cited by 42 publications

(34 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 ). This result is concurrent with those of previous studies ( 11 , 14 , 21 , 26 ). Furthermore, Spearman's correlation analysis (data not shown) revealed that the serum LDH level has a negative correlation with the expression of LDHD (P=0.028).…”

Section: Resultssupporting

confidence: 93%

Prognostic value of D‑lactate dehydrogenase in patients with clear cell renal cell carcinoma

Wang

Wan

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Lactate dehydrogenase (LDH) is an enzyme involved in anaerobic glycolysis and is associated with the prognosis of patients with renal cell carcinoma (RCC). The human genome has four LDH genes: LDHA, LDHB, LDHC and LDHD. In order to determine which of these four LDH genes may predict clear cell RCC (ccRCC), a total of 509 patients with ccRCC from The Cancer Genome Atlas (TCGA) cohort and 192 patients with ccRCC from the Fudan University Shanghai Cancer Centre (FUSCC) cohort were enrolled in the present study. The expression profiles of LDHD genes in the TCGA cohort were obtained from the TCGA RNAseq database. The Cox proportional hazards regression model and Kaplan-Meier curves were used to assess relative factors. The LDH family genes that were revealed to have an association with overall survival (OS) were further validated in the FUSCC cohort. In the TCGA cohort, following Cox proportional hazards analysis, LDHD expression (P=0.0400; hazard ratio, 0.872; 95% confidence interval, 0.764–0.994) was revealed to be predictive of the prognosis of patients with ccRCC. Further analysis revealed that low LDHD expression (P<0.0001) was significantly associated with a poor prognosis in terms of OS. Additionally, the expression of LDHD (P<0.0001) was significantly different in patients with ccRCC compared with paired controls. In the FUSCC cohort, low LDHD expression was also associated with a poor OS (P=0.0103), and the tumour pathological T stage was a factor that influenced the expression of LDHD (P=0.0120). Furthermore, the expression of LDHD influenced the serum LDH level (P=0.0126). The downregulation of LDHD expression may be a predictor of poor prognosis in patients with ccRCC.

show abstract

Section: Resultssupporting

confidence: 93%

Prognostic value of D‑lactate dehydrogenase in patients with clear cell renal cell carcinoma

Wang

Wan

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Some studies had demonstrated serum LDH could be an effective biomarker to predict the prognosis of small cell lung cancer, renal cell carcinoma and colorectal cancer. [ 36 – 38 ] In an animal study, Nakamura and Kitagawa [ 39 ] transplanted the human osteosarcomas to nude mice and found LDH could be a biomarker to predict the prognosis of these mice. Some cohort studies also reported serum LDH was an indicator of prognosis in osteosarcoma patients.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma

Lan

Cai

et al. 2018

Medicine

View full text Add to dashboard Cite

Backgrounds:A large number of studies have reported the relationships between serum lactate dehydrogenase (LDH) and prognosis of osteosarcoma. However, the result is still controversial and no consensus has been reached. Therefore, we performed a meta-analysis to evaluate the prognostic role of serum LDH in osteosarcoma patients.Methods:We performed the systematic computerized search for eligible articles from PubMed, Embase, and Cochrane databases until December 21, 2017. The pooled hazard ratio (HR) and 95% confidence intervals (CIs) of overall survival (OS) and event-free survival (EFS) were obtained to assess the prognostic value of serum LDH.Results:A total of 18 studies with 2543 osteosarcoma patients were included. Overall, 15 studies assessed the elevated serum LDH level on OS and the pooled HR was 1.87 (95% CI = 1.58–2.20). Meanwhile, the pooled HR to evaluate the relationship between serum LDH and EFS in 9 studies was 1.78 (95% CI = 1.51–2.10). The same results were acquired when these studies were stratified by Enneking stage, geographic region, and sample size. No heterogeneity existed between these subgroups (P > .05). Begg's funnel plot and Egger's test (OS: P = .04; EFS: P = .34) showed that possible publication bias might exist in OS studies. Sensitivity analysis suggested the pooled HR was robust.Conclusions:This meta-analysis demonstrates that elevated serum LDH level is apparently associated with lower EFS rate and serum LDH could be a prognostic biomarker for osteosarcoma patients.

show abstract

“…It has been confirmed that serum C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), interleukin (IL)-18, and IL-17A play important roles in the progression of many infectious, inflammatory, malignant and other diseases. [22][23][24][25][26][27] Previous studies have shown a correlation between the severity of MPP and serum CRP, ferritin, LDH, and IL-18. [28][29][30] Although serum IL-17A in MPP has seldom been reported, IL-17A in bronchoalveolar lavage fluid (BALF) has been shown to play critical roles in the occurrence and development of pulmonary diseases, including acute lung injury 31 and MPP.…”

Section: Introductionmentioning

confidence: 98%

<p>Clinical Role of Serum Interleukin-17A in the Prediction of Refractory <em>Mycoplasma pneumoniae</em> Pneumonia in Children</p>

Jiu-ling¹,

Ji²,

Wang³

et al. 2020

IDR

View full text Add to dashboard Cite

Background: Mycoplasma pneumoniae pneumonia (MPP) is a common community-acquired pneumonia (CAP) in children, which may become refractory MPP (RMPP) to treatment. Objective: The purpose of this study was to evaluate the clinical utility of measuring serum interleukin (IL)-17A to predict RMPP. Patients and Methods: A retrospective clinical study at a single pediatric center included a review of the medical records of all children hospitalized for CAP between November 2015 and October 2019. The diagnosis of MPP was based on clinical presentation, chest radiography, and measurement of serum anti-Mycoplasma immunoglobulin IgM antibody titer using the microparticle agglutination method or sputum samples for Mycoplasma pneumoniae by PCR. Serum levels of IL-18 and IL-17A were determined by ELISA. Results: Of the 625 children diagnosed with CAP, there were 154 children with MPP and without underlying diseases who were divided into a non-refractory MPP (NRMPP) group (n = 109) and a RMPP group (n = 45). The RMPP group had a higher incidence of tachypnea, cyanosis, hypoxia, segmental or lobar pneumonia, pleural effusion, and a longer period of hospitalization compared with NRMPP group (all P-values < 0.05). A serum IL-17A level above 10.8 pg/mL was a predictor for RMPP: area under the curve (AUC) 0.822; standard error (SE) 0.039; 95% confidence interval (CI) 0.746-0.897; diagnostic sensitivity and specificity of 77.8% and 77.1%, respectively. An LDH level above 436.5 IU/L and an IL-18 level above 464.5 pg/mL were the second most useful markers for RMPP: AUC 0.

show abstract

Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Cited by 42 publications

References 48 publications

Prognostic value of D‑lactate dehydrogenase in patients with clear cell renal cell carcinoma

Prognostic value of D‑lactate dehydrogenase in patients with clear cell renal cell carcinoma

Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma

<p>Clinical Role of Serum Interleukin-17A in the Prediction of Refractory <em>Mycoplasma pneumoniae</em> Pneumonia in Children</p>

Contact Info

Product

Resources

About